Exenatide
exendin-4, synthetic exendin-4, AC2993, exenatide extended-release, LY2148568, Byetta, Bydureon
Exenatide is a synthetic copy of exendin-4, a 39-amino-acid peptide originally isolated from the venom of the Gila monster (Heloderma suspectum). It was the first GLP-1 receptor agonist licensed anywhere in the world, approved in the United States in 2005 for type 2 diabetes. Both the twice-daily and once-weekly formulations have since been discontinued commercially, but the compound remains the reference molecule for the entire incretin drug class.
Mechanism
Exenatide is an agonist at the GLP-1 receptor, a class B1 G-protein-coupled receptor. Exendin-4 shares only about 53% sequence identity with human GLP-1, but the critical difference is glycine rather than alanine at position 2, which removes the dipeptidyl peptidase-4 (DPP-4) cleavage site and gives the peptide a plasma survival time roughly two orders of magnitude longer than native GLP-1. A nine-residue C-terminal extension forms a so-called Trp-cage that stabilises the helical conformation and contributes substantially to receptor affinity.
Receptor occupancy couples through Gs to adenylyl cyclase, raising cyclic AMP and activating protein kinase A and Epac2 in the pancreatic beta cell. The downstream effects are glucose-dependent amplification of insulin secretion (which is why monotherapy rarely causes hypoglycaemia), suppression of inappropriately elevated glucagon release from alpha cells, delayed gastric emptying, and central appetite suppression via receptors in the area postrema and hypothalamus. Short-acting exenatide produces a particularly pronounced and sustained delay in gastric emptying, because intermittent exposure avoids the receptor desensitisation seen with continuously acting long-duration agonists. Exenatide is cleared predominantly by glomerular filtration and proteolysis in the kidney, which is why renal impairment materially alters exposure.
What the research shows
The three AMIGO trials, each 30 weeks and placebo-controlled on a different oral background therapy, consistently produced placebo-adjusted HbA1c reductions of roughly 0.8-0.9 percentage points at the 10 microgram twice-daily dose, together with progressive weight loss of about 2-3 kg. In the metformin study the within-group change was -0.78 percentage points against +0.08 on placebo, with weight falling 2.8 kg. Nausea affected 40-50% of participants and was the main reason for withdrawal. DURATION-1 subsequently showed that the once-weekly microsphere formulation was more effective than twice-daily dosing on HbA1c (1.9 versus 1.5 percentage points) with less nausea but more injection-site nodules.
The most important result is arguably a negative one. EXSCEL randomised 14,752 people with type 2 diabetes to once-weekly exenatide or placebo for a median of 3.2 years and found a hazard ratio of 0.91 (95% CI 0.83-1.00) for major adverse cardiovascular events, which did not cross the prespecified threshold for superiority. Exenatide is therefore cardiovascular-safe but, unlike liraglutide, semaglutide and dulaglutide, was not shown to be cardioprotective. Exenatide also generates anti-drug antibodies far more often than human GLP-1-based analogues, and high antibody titres attenuate glycaemic response in a small minority of patients.
Evidence assessment
High-quality evidence
Exenatide was supported by three replicated 30-week placebo-controlled phase 3 trials (the AMIGO programme), multiple head-to-head comparator trials, and a 14,752-patient cardiovascular outcomes trial. It carried approved labelling in the United States, European Union and United Kingdom for over fifteen years. The evidence base is unambiguously strong even though the products are no longer marketed. All five cited studies were individually verified against PubMed.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Preclinical only
HbA1c changed by -0.78 percentage points on 10 micrograms twice daily and -0.40 on 5 micrograms, against +0.08 on placebo, giving a placebo-adjusted reduction of about 0.86 points at the higher dose. Weight fell 2.8 kg on 10 micrograms. HbA1c of 7% or below was achieved by 46%, 32% and 13% respectively.
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Preclinical only
Placebo-adjusted HbA1c reduction of about 0.86 percentage points on 10 micrograms twice daily. Hypoglycaemia was appreciably more frequent than in the metformin study, reflecting the sulfonylurea background.
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Preclinical only
HbA1c reductions of roughly 0.8 percentage points with weight loss, replicating the two companion AMIGO trials on a third background regimen.
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Preclinical only
Once-weekly extended-release exenatide reduced HbA1c by 1.9 percentage points versus 1.5 for twice-daily dosing, and 77% versus 61% reached HbA1c of 7.0% or below. Less nausea but more injection-site nodules with the weekly formulation; weight loss was comparable.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes Preclinical only
Major adverse cardiovascular events occurred with a hazard ratio of 0.91 (95% CI 0.83-1.00), which did not meet the prespecified superiority threshold. Exenatide was confirmed cardiovascular-safe but not shown to be cardioprotective.
Safety
Nausea, vomiting and diarrhoea dominate and are dose-related and largely early. Hypoglycaemia is uncommon with exenatide alone but frequent when it is combined with a sulfonylurea or insulin. The extended-release formulation causes injection-site nodules in a substantial minority. Post-marketing reports of acute pancreatitis led to label warnings, and reports of acute kidney injury and worsening renal function reflect renal clearance of the peptide; use was not recommended below an eGFR of 30 mL/min/1.73m2. Rodent carcinogenicity studies with the extended-release formulation showed thyroid C-cell tumours, producing a boxed warning covering medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Gallbladder disease and, rarely, injection-site abscess have also been reported. Immunogenicity is higher than for human GLP-1 analogues.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Authorised across the European Union from November 2006 and subsequently converted to a Great Britain marketing authorisation regulated by the MHRA. The twice-daily product was discontinued in the UK, and the once-weekly prolonged-release presentation has also been discontinued, with UK supply notifications issued as stocks were exhausted. Prescription-only medicine; not a controlled drug. Neither formulation is currently obtainable in routine UK practice. Readers should check current national supply notices, as discontinuation dates are administrative and have been revised more than once. |
| United States | Approved by the FDA in April 2005 as a twice-daily immediate-release injection and in January 2012 as a once-weekly extended-release suspension, both for glycaemic control in adults with type 2 diabetes; the once-weekly product was later extended to children aged 10 and over. It was never licensed as a weight-management medicine in its own right. Both formulations have been discontinued by the marketing authorisation holder for commercial rather than safety reasons. Prescription-only while marketed; not a controlled substance. |
| WADA (sport) | Not prohibited. GLP-1 receptor agonists as a class do not appear on the WADA Prohibited List, and exenatide is not individually listed. WADA operates a separate Monitoring Programme that is revised annually and does not carry sanctions; its current contents should be checked against the list in force for the relevant year rather than assumed. |
Questions
Yes, in origin. Exendin-4 was identified in the venom of the Gila monster by John Eng in the early 1990s and found to be a long-acting GLP-1 receptor agonist. The medicine itself is chemically synthesised, not extracted from animals, but the sequence is genuinely reptilian rather than a human peptide.
For commercial reasons, not safety. Newer agents such as semaglutide, dulaglutide and tirzepatide deliver larger reductions in HbA1c and body weight, and several also demonstrated cardiovascular benefit that exenatide did not. Demand collapsed and the manufacturer withdrew both formulations from major markets.
Exenatide is a lizard-derived exendin-4 peptide; semaglutide is a modified human GLP-1 sequence with a fatty-acid side chain that binds albumin. The practical consequences are that exenatide provokes anti-drug antibodies more often, is cleared renally, and produces smaller reductions in HbA1c and weight.
It produces modest weight loss, typically 2-3 kg over 30 weeks in trials and somewhat more with longer treatment. That is considerably less than modern GLP-1 receptor agonists achieve, and exenatide was never licensed as an obesity treatment in any major jurisdiction.